Abstract

Zanamivir, the active ingredient of the antiviral drug Relenza, is the most potent of the four currently approved neuraminidase inhibitors for treatment of pandemic strains of influenza. A combination of solution creeping and vapor diffusion of antisolvent was successfully applied to obtain two crystalline polymorphic dihydrates and to accomplish the first structure determination of zanamivir with X-ray diffraction.